Erectile Dysfunction

Hypnion is developing a compound, HY10275, which is of interest to Lilly.

The compound is undergoing testing.

-Mike Barris and Josee Rose; 201-938-5658; mike.barris@dowjones.com; josee.rose@dowjones.com (END) Dow Jones Newswires 04-16-07 0713ET Copyright (c) 2007 Dow Jones & Company, Inc.

Breaking News Archive For more answers to your tough investing questions, subscribe to SmartMoney Magazine.

To license this content, click here .textlinks { float:left; width:295px; padding:0px 0 5px 10px; margin-left: 6px; text-indent: -6px; height: 30px; } ADVERTISEMENTS Switch to Scottrade and get up to $100 back!

Open an account today!

$0 STOCK TRADES.

No gimmicks.

10/day, 40/mo, 3.50 thereafter.

Zecco.com New online broker offers $0 stock trades: 10/day, 40/month, then $3.50 Introducing Dell Virtual Office.

Step inside.

Introducing the Blackberry 8800 from Cingular, the new AT&T The most important guide to investing in China for 2007 - available online now - FREE A surprising prediction by Ken Fisher - Get his forecast here!

The Motley Fool co-founders David & Tom Gardner´s TOP 2 stock picks for 2007 - FREE Report!

Power E*TRADE: Low Trade Pricing.

Get 100 Commission-Free Trades Switch to TD AMERITRADE and trade free for 45 days + get $1...

Read more...